FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000723196> ?p ?o ?g. }

• W2000723196 endingPage "1626" @default.
• W2000723196 startingPage "1621" @default.
• W2000723196 abstract "To evaluate the toxicity, pharmacological and biological properties of ATN-161, a five -amino-acid peptide derived from the synergy region of fibronectin, adult patients with advanced solid tumours were enrolled in eight sequential dose cohorts (0.1-16 mg kg(-1)), receiving ATN-161 administered as a 10-min infusion thrice weekly. Pharmacokinetic sampling of blood and urine over 7 h was performed on Day 1. Twenty-six patients received from 1 to 14 4-week cycles of treatment. The total number of cycles administered to all patients was 86, without dose-limiting toxicities. At dose levels above 0.5 mg kg(-1), mean total clearance and volume of distribution showed dose-independent pharmacokinetics (PKs). At 8.0 and 16.0 mg kg(-1), clearance of ATN-161 was reduced, suggesting saturable PKs. Dose escalation was halted at 16 mg kg(-1) when drug exposure (area under the curve) exceeded that associated with efficacy in animal models. There were no objective responses. Six patients received more than four cycles of treatment (>112 days). Three patients received 10 or more cycles (> or =280 days). ATN-161 was well tolerated at all dose levels. Approximately, 1/3 of the patients in the study manifested prolonged stable disease. These findings suggest that ATN-161 should be investigated further as an antiangiogenic and antimetastatic cancer agent alone or with chemotherapy." @default.
• W2000723196 created "2016-06-24" @default.
• W2000723196 creator A5010671566 @default.
• W2000723196 creator A5015470850 @default.
• W2000723196 creator A5015582820 @default.
• W2000723196 creator A5016035764 @default.
• W2000723196 creator A5019283713 @default.
• W2000723196 creator A5029643115 @default.
• W2000723196 creator A5045107557 @default.
• W2000723196 creator A5048868022 @default.
• W2000723196 creator A5056500955 @default.
• W2000723196 creator A5065530824 @default.
• W2000723196 creator A5068392079 @default.
• W2000723196 creator A5074305095 @default.
• W2000723196 creator A5085559355 @default.
• W2000723196 date "2006-05-16" @default.
• W2000723196 modified "2023-10-15" @default.
• W2000723196 title "Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours" @default.
• W2000723196 cites W1233276 @default.
• W2000723196 cites W1504989678 @default.
• W2000723196 cites W1573363574 @default.
• W2000723196 cites W1783580437 @default.
• W2000723196 cites W1857696541 @default.
• W2000723196 cites W1974778285 @default.
• W2000723196 cites W1977224950 @default.
• W2000723196 cites W1982005589 @default.
• W2000723196 cites W1988175245 @default.
• W2000723196 cites W1998033848 @default.
• W2000723196 cites W2000000541 @default.
• W2000723196 cites W2000613344 @default.
• W2000723196 cites W2001753204 @default.
• W2000723196 cites W2014313582 @default.
• W2000723196 cites W2027347344 @default.
• W2000723196 cites W2029773366 @default.
• W2000723196 cites W2031268700 @default.
• W2000723196 cites W2038145387 @default.
• W2000723196 cites W2038561272 @default.
• W2000723196 cites W2063897621 @default.
• W2000723196 cites W2071958672 @default.
• W2000723196 cites W2076668534 @default.
• W2000723196 cites W2084223070 @default.
• W2000723196 cites W2104311705 @default.
• W2000723196 cites W2105300288 @default.
• W2000723196 cites W2109069224 @default.
• W2000723196 cites W2128373232 @default.
• W2000723196 cites W2131889462 @default.
• W2000723196 cites W2137344766 @default.
• W2000723196 cites W2139248078 @default.
• W2000723196 cites W2155524198 @default.
• W2000723196 cites W2155807129 @default.
• W2000723196 cites W2157769714 @default.
• W2000723196 cites W2169992085 @default.
• W2000723196 cites W2320277402 @default.
• W2000723196 cites W4322717319 @default.
• W2000723196 cites W84647915 @default.
• W2000723196 doi "https://doi.org/10.1038/sj.bjc.6603171" @default.
• W2000723196 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361324" @default.
• W2000723196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16705310" @default.
• W2000723196 hasPublicationYear "2006" @default.
• W2000723196 type Work @default.
• W2000723196 sameAs 2000723196 @default.
• W2000723196 citedByCount "148" @default.
• W2000723196 countsByYear W20007231962012 @default.
• W2000723196 countsByYear W20007231962013 @default.
• W2000723196 countsByYear W20007231962014 @default.
• W2000723196 countsByYear W20007231962015 @default.
• W2000723196 countsByYear W20007231962016 @default.
• W2000723196 countsByYear W20007231962017 @default.
• W2000723196 countsByYear W20007231962018 @default.
• W2000723196 countsByYear W20007231962019 @default.
• W2000723196 countsByYear W20007231962020 @default.
• W2000723196 countsByYear W20007231962021 @default.
• W2000723196 countsByYear W20007231962022 @default.
• W2000723196 countsByYear W20007231962023 @default.
• W2000723196 crossrefType "journal-article" @default.
• W2000723196 hasAuthorship W2000723196A5010671566 @default.
• W2000723196 hasAuthorship W2000723196A5015470850 @default.
• W2000723196 hasAuthorship W2000723196A5015582820 @default.
• W2000723196 hasAuthorship W2000723196A5016035764 @default.
• W2000723196 hasAuthorship W2000723196A5019283713 @default.
• W2000723196 hasAuthorship W2000723196A5029643115 @default.
• W2000723196 hasAuthorship W2000723196A5045107557 @default.
• W2000723196 hasAuthorship W2000723196A5048868022 @default.
• W2000723196 hasAuthorship W2000723196A5056500955 @default.
• W2000723196 hasAuthorship W2000723196A5065530824 @default.
• W2000723196 hasAuthorship W2000723196A5068392079 @default.
• W2000723196 hasAuthorship W2000723196A5074305095 @default.
• W2000723196 hasAuthorship W2000723196A5085559355 @default.
• W2000723196 hasBestOaLocation W20007231961 @default.
• W2000723196 hasConcept C112705442 @default.
• W2000723196 hasConcept C126322002 @default.
• W2000723196 hasConcept C126894567 @default.
• W2000723196 hasConcept C2776694085 @default.
• W2000723196 hasConcept C29730261 @default.
• W2000723196 hasConcept C71924100 @default.
• W2000723196 hasConcept C90924648 @default.
• W2000723196 hasConcept C98274493 @default.
• W2000723196 hasConceptScore W2000723196C112705442 @default.

• next